Ipilimumab/Nivolumab Regimen

Identifier: CI-DRUG-00000310
Entity page: /drug/ipilimumab-nivolumab-regimen ↗
Edges: 78

Neighbours: 17 cancers2 variants10 trials
Drawn: 29 of 29 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Ipilimumab/Nivolumab Regimen predicts response to …PREDICTS_RESPONSE_TO2 of 2
← predicts response to	High 2 source records aggregated	sensitivity	A	Malignant Colorectal Neoplasm	2	Curated	civic	graph →
← predicts response to	High 3 source records aggregated	sensitivity	B

Ipilimumab/Nivolumab Regimen investigated for …INVESTIGATED_FOR3 of 3
→ investigated for	Malignant Colorectal Neoplasmsubtype 2 source records aggregated	supports	A	Malignant Colorectal Neoplasm	2	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype 2 source records aggregated	supports	B	Lung Non-Small Cell Carcinoma	2	Curated	civic	graph →
→ investigated for	Lung Adenocarcinomasubtype	supports	B	Lung Adenocarcinoma	1	Curated	civic	graph →

Ipilimumab/Nivolumab Regimen investigated for …INVESTIGATED_FOR3 of 3

→ investigated for

Malignant Colorectal Neoplasmsubtype

2 source records aggregated

supports

Malignant Colorectal Neoplasm

Curated

Ipilimumab/Nivolumab Regimen investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 30show all (up to 200)
→ investigated in trials for	Melanoma 11 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 10 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Renal Cell Carcinoma 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Renal Cell Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Mesothelioma 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Mesothelioma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Hepatocellular Carcinoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Kidney Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Kidney Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Skin Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Skin Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Uveal Melanoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Uveal Melanoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Solid Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Brain Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Brain Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cutaneous Melanoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cutaneous Melanoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioblastoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →

Ipilimumab/Nivolumab Regimen studied in …STUDIED_INderived10 of 43show all (up to 200)
→ studied in	NCT07815574Phase 3 · not yet recruiting iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma · 43 trials list this drug (22 active)	—	—	Malignant Skin Neoplasm,Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04090710Phase 2 · completed SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer · 43 trials list this drug (22 active)	—	—	Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07740941Phase 2 · not yet recruiting NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma · 43 trials list this drug (22 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07501117Phase 1 · recruiting Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma · 43 trials list this drug (22 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05933265Phase 1/Phase 2 · active not recruiting Study of LP-184 in Patients With Advanced Solid Tumors · 43 trials list this drug (22 active)	—	—	Solid Neoplasm,Glioblastoma,Lung Non-Small Cell Carcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT07563738Phase 1/Phase 2 · recruiting A 2-part Phase 1/2 Open-label Trial on ODM-212 · 43 trials list this drug (22 active)	—	—	Malignant Mesothelioma,Malignant Pancreatic Neoplasm,Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07075120Phase 1 · recruiting Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer · 43 trials list this drug (22 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04665206Phase 1/Phase 2 · recruiting Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors · 43 trials list this drug (22 active)	—	—	Adult Solid Neoplasm,Malignant Mesothelioma,Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07436390NA · completed IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma · 43 trials list this drug (22 active)	—	—	Malignant Skin Neoplasm,Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06999980Phase 2 · recruiting Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) · 43 trials list this drug (22 active)	—	—	Cutaneous Melanoma,Mucosal Melanoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths